Welcome to our dedicated page for Io Biotech SEC filings (Ticker: IOBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IO Biotech, Inc. (Nasdaq: IOBT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed with the Securities and Exchange Commission. IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform, with its lead candidate Cylembio® (IO102-IO103) in advanced clinical development.
Through these filings, investors can review material event disclosures related to IO Biotech’s business. Recent Form 8-K reports describe topline and detailed results from the pivotal Phase 3 IOB-013/KN-D18 trial of Cylembio plus KEYTRUDA® (pembrolizumab) in advanced melanoma, updates on regulatory interactions with the U.S. Food and Drug Administration, and the company’s plans to design a potential new registrational study. Other 8-K filings outline financial results for quarterly periods, restructuring and workforce reduction plans, unregistered sales of equity securities tied to a European Investment Bank loan facility, and changes in executive roles and compensation arrangements.
Stock Titan’s interface is designed to surface key elements of IO Biotech’s filings, such as clinical and regulatory milestones, cash runway commentary, term loan and warrant terms, and board or management actions, while linking back to the full EDGAR documents for detailed review. Users can also monitor securities registration information confirming that IO Biotech’s common stock, par value $0.001 per share, is listed on The Nasdaq Stock Market LLC under the symbol IOBT.
In addition to current reports, investors may use this page to track how IO Biotech describes the status of its Cylembio development program, its broader T-win platform pipeline, and its capital resources over time. AI-powered tools on Stock Titan help summarize complex sections of filings, making it easier to interpret disclosures about clinical trial outcomes, regulatory feedback, financing transactions, and corporate restructuring measures.
IO Biotech, Inc. reported that Nasdaq has notified the company it is not meeting the Nasdaq Global Select Market requirement that market value of listed securities be at least
The company has 180 calendar days, until
If IO Biotech does not regain compliance by the deadline, Nasdaq may initiate delisting of its common stock, though the company would have the opportunity to appeal under Nasdaq’s procedures. The notice does not immediately affect trading of IO Biotech’s shares, which continue on the Nasdaq Global Select Market.
IO Biotech, Inc. investor Jorey Chernett filed Amendment No. 1 to a Schedule 13G reporting beneficial ownership of 4,543,532 shares of IO Biotech common stock, representing 6.3% of the class as of December 31, 2025.
Chernett reports sole voting and dispositive power over all 4,543,532 shares, with no shared voting or investment authority and no membership in a filing group. The certification states that the shares were not acquired to change or influence control of IO Biotech.
IO Biotech, Inc. received a Schedule 13G filing from Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen. They report beneficial ownership, through Point72 Associates, of 4,027,112 shares of IO Biotech common stock, representing 5.6% of the class as of February 5, 2026.
The reporting persons have shared voting and shared dispositive power over these shares and no sole voting or dispositive power. They state the securities were not acquired and are not held for the purpose of changing or influencing control of IO Biotech. The filing is made jointly under a Joint Filing Agreement.
IO Biotech, Inc. reported that its board approved a restructuring and workforce reduction plan intended to significantly cut operating expenses while the company explores a range of strategic alternatives. The plan is expected to result in a significant global reduction of the company’s workforce.
The company expects to incur one-time charges and cash expenditures of approximately $2.4 million to $2.6 million, mainly for wages, severance, healthcare continuation, earned vacation and related termination costs, primarily during the first quarter of 2026. IO Biotech also notified Chief Medical Officer Qasim Ahmad, M.D., a named executive officer, that his employment will end on February 15, 2026.
The company announced it has retained Raymond James & Associates, Inc. as exclusive financial advisor to assist in its ongoing exploration of strategic alternatives, and issued a press release describing the restructuring and workforce reduction plan, which is attached as an exhibit.
Novo Holdings A/S has reduced its stake in IO Biotech, Inc. This amendment reports that on January 21, 2026, Novo Holdings A/S sold 2,512,453 shares of IO Biotech common stock in open market transactions at prices ranging from
After these sales, Novo Holdings A/S beneficially owns 2,469,135 shares of IO Biotech common stock issuable upon the exercise of immediately exercisable warrants, representing approximately
IO Biotech, Inc. filed a current report stating that on January 21, 2026 it issued a press release announcing that it plans to explore strategic alternatives. This means the company is formally beginning a review of potential options for its future direction, which can range from continuing its current plan to considering significant corporate changes, depending on what the review determines. The press release describing this process is attached as an exhibit to the report.
IO Biotech, Inc. reported that its Senior Vice President and Chief Accounting Officer, Brian Burkavage, has informed the company of his intent to resign effective December 12, 2025 to pursue another opportunity. The company stated that his resignation is not due to any dispute or disagreement with the company.
The company’s Chief Financial Officer, Amy Sullivan, has been designated as IO Biotech’s principal accounting officer, effective upon Mr. Burkavage’s departure. Her background is described in the company’s 2025 definitive proxy statement. IO Biotech noted that no new compensatory arrangements will be entered into with Ms. Sullivan in connection with her additional role.
IO Biotech, Inc. announced that it will participate in the Jefferies Global Healthcare Conference beginning on November 18, 2025. In connection with this event, the company prepared an updated corporate investor presentation that it plans to use at the conference and in meetings with investors.
The updated investor presentation, referred to as the Investor Deck, was posted to the company’s website on November 18, 2025 and is also provided as an exhibit to this report. The company notes that this material is being furnished rather than filed under U.S. securities laws.
IO Biotech (IOBT) reported Q3 results showing lower operating expenses but continued losses and tighter liquidity. Operating costs were $19.4M in Q3 (vs. $26.5M a year ago), driving a net loss of $8.4M. For the first nine months, operating expenses were $65.1M and net loss was $57.0M. Cash, cash equivalents and restricted cash were $30.9M at September 30, 2025.
The company disclosed substantial doubt about its ability to continue as a going concern, stating current cash is not sufficient to fund operations for at least 12 months from issuance. To extend runway, IO Biotech drew on the European Investment Bank facility, funding €10.0M (Tranche A) and €12.5M (Tranche B), resulting in $16.7M term loan debt, net, and issuing related liability-classified warrants valued at $3.4M at quarter-end.
Management also launched a restructuring on September 26, 2025 to reduce workforce by roughly 50%, expecting $1.0–$1.5M in charges, with $0.9M recognized in Q3. The company raised $6.6M net through its ATM (3,810,040 shares issued). Shares outstanding were 69,692,179 as of September 30, 2025; 71,948,842 were outstanding as of November 10, 2025.
IO Biotech, Inc. (IOBT) furnished an 8-K announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025 and an operations update. The press release is attached as Exhibit 99.1.
The company states the information under Item 2.02 is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically referenced.